Last Price$8.511.2%
Market Cap$1,347.5M
LTM Net Debt
($316.3M)
YoY Growth
+185.0%
3Y CAGR
+44.3%
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
12.3% undervalued
Ocular Therapeutix, Inc. Net Debt
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt | ($19.8M) | ($15.0M) | ($60.0M) | ($89.8M) | ($52.5M) | ($23.5M) | ($29.3M) | $6,032.0K | ($168.3M) | ($103.6M) | ($36.4M) | ($112.4M) | ($316.3M) |
Overvalued or undervalued?
Check the intrinsic value for OCUL
and see if it's the right time to invest.
Ocular Therapeutix, Inc. (OCUL) Net Debt comparison analysis
General
LTM Net Debt
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Ocular Therapeutix, Inc.OCUL
($316.3M)
185.0%
44.3%
N/A
Median Peer Set
($1,499.5M)
0.0%
6.5%
9.5%
Royalty Pharma plcRPRX
$5,841.4M
3.6%
10.8%
1.4%
Summit Therapeutics Inc.SMMT
($405.1M)
405.5%
80.0%
61.5%
BioMarin Pharmaceutical Inc.BMRN
($535.0M)
N/A
N/A
N/A
Alnylam Pharmaceuticals, Inc.ALNY
($1,398.5M)
N/A
77.5%
7.9%
BeiGene, Ltd.BGNE
($1,600.5M)
(38.3%)
(20.8%)
11.1%
United Therapeutics CorporationUTHR
($2,967.0M)
29.3%
2.2%
16.2%
Vertex Pharmaceuticals IncorporatedVRTX
($4,366.4M)
(54.9%)
(12.7%)
6.8%
Regeneron Pharmaceuticals, Inc.REGN
($15.9B)
95.6%
20.5%
22.6%
BioNTech SEBNTX
($17.1B)
(6.3%)
116.9%
99.8%
argenx SEARGX
N/A
N/A
N/A
N/A
OCUL key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 (100.0%) | 0.8 0.0% | 1.8 126.7% | 1.9 7.8% | 1.9 1.9% | 2.0 3.5% | 4.2 112.4% | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% |
| Cost of Goods Sold (COGS) | 0.0 | 10.5 | 0.1 | 0.3 | 0.4 | 0.5 | 0.5 | 2.3 | 2.1 | 4.4 | 4.5 | 5.3 | 5.6 |
% margin | 0.0 30.0% | (10.5) 0.0% | 0.7 88.2% | 1.4 81.8% | 1.4 76.5% | 1.5 76.2% | 1.5 76.6% | 1.9 45.0% | 15.3 88.0% | 39.1 89.9% | 47.0 91.2% | 53.2 91.0% | 58.1 91.2% |
| Operating Expenses | 13.7 | 12.9 | 27.8 | 39.6 | 44.8 | 63.4 | 60.6 | 87.7 | 78.2 | 117.2 | 125.6 | 135.5 | 229.9 |
| Research & Development Expenses (R&D) | 11.5 | 10.5 | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 8.9 | 13.0 | 17.7 | 32.5 | 23.7 | 46.6 | 49.5 | 67.1 | 72.1 | 74.5 | 102.2 |
% margin | (13.7) (136,710.0%) | (12.9) 0.0% | (27.1) (3,509.6%) | (38.2) (2,182.7%) | (43.3) (2,296.0%) | (61.9) (3,220.1%) | (59.1) (2,970.8%) | (85.8) (2,029.9%) | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.9 | 1.2 | 0.2 | 0.0 | 0.8 | 4.0 | 20.3 |
| Interest Expense | 0.4 | 0.4 | 1.1 | 1.7 | 1.7 | 1.9 | 1.7 | 6.1 | 6.8 | 6.7 | 7.0 | 11.3 | 13.6 |
| Pre-tax Income | (14.1) | (13.3) | (28.6) | (39.7) | (44.7) | (63.4) | (60.0) | (86.4) | (155.6) | (6.6) | (71.0) | (80.7) | (193.5) |
% effective tax rate | 0.3 (2.3%) | 0.5 (3.4%) | 0.1 (0.5%) | 1.0 (2.5%) | 0.8 (1.8%) | 0.3 (0.4%) | (2.3) 3.8% | 3.6 (4.1%) | 4.0 (2.6%) | 4.3 (64.9%) | (7.6) 10.7% | 0.0 0.0% | 0.0 0.0% |
% margin | (14.1) (140,930.0%) | (13.3) 0.0% | (28.6) (3,710.9%) | (39.7) (2,271.3%) | (44.7) (2,369.0%) | (63.4) (3,296.2%) | (57.7) (2,899.1%) | (89.9) (2,127.6%) | (159.6) (917.3%) | (10.8) (24.8%) | (63.4) (123.2%) | (80.7) (138.1%) | (193.5) (303.7%) |
| EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.14) | (0.83) | (1.09) | (1.22) |
| Diluted EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.13) | (0.83) | (1.02) | (1.22) |
% margin | (13.3) (133,120.0%) | (12.5) 0.0% | (27.0) (3,495.1%) | (37.3) (2,129.7%) | (42.1) (2,233.3%) | (59.9) (3,113.3%) | (56.0) (2,811.7%) | (77.7) (1,839.2%) | (146.1) (839.5%) | (75.6) (173.7%) | (61.9) (120.2%) | (66.4) (113.6%) | (176.1) (276.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Ocular Therapeutix, Inc.'s Net Debt?
As of today, Ocular Therapeutix, Inc.'s last 12-month Net Debt is ($316.3M), based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Ocular Therapeutix, Inc.'s Net Debt growth rate?
Over the last year, Ocular Therapeutix, Inc.'s Net Debt growth was 185.0%. The average annual Net Debt growth rates for Ocular Therapeutix, Inc. have been 33.9% over the past three years, N/A over the past five years.
3) Is Ocular Therapeutix, Inc.'s Net Debt growth rate Good?
Over the last year, Ocular Therapeutix, Inc.'s Net Debt growth was 185.0%, which is higher than industry growth of (0.1%). It indicates that Ocular Therapeutix, Inc.'s Net Debt growth is Bad.